Therapeutic Delivery – Multimedia

The pandemic has ushered in a vaccines “golden era”. Long-term investment in vaccine manufacturing has been prioritized, as has the pursuit of novel vaccine platforms. In this infographic, we explore recent advances in vaccine research and development.

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. Furthermore, recent estimates predict that as many as one in two people could develop a form of cancer in their lifetime.

Lipid nanoparticles (LNPs) have emerged as effective delivery vehicles for mRNA vaccines and nucleic acid-based drugs. Hence, the analysis of their composition, stability, and biological interactions is essential in drug development and delivery.

Liposomes are spherical vesicle having at least one lipid bilayer. Liposomes can be used as a vehicle (delivery system) for the administration of nutrients and pharmaceutical drugs.

Speaking at the Vaccine Research & Development 2022 online symposium, Nikolai Petrovsky, Professor of Medicine at FLinder's University, delivered his talk on the first Australian-developed vaccine in over 40 years.

Lipid nanoparticles (LNPs) are effective non-viral vectors, which are widely used delivery vehicles for genetic medicines. It is therefore important to understand and limit LNP-related impurities to help ensure genetic product integrity and mitigate risks to patient safety and product efficacy.

Lipid nanoparticles (LNPs), comprised of ionizable lipids, are used to deliver oligonucleotides to work as therapeutics or to stimulate the immune system, as in the initial mRNA-based COVID vaccines.

Messenger RNA (mRNA) therapy enables the body to make the proteins needed to prevent, treat or cure diseases but, unlike traditional biologics, mRNAs are large and delicate molecules that need to be protected by lipid nanoparticles (LNPs) on the journey to reach target cells.

Watch this short presentation to learn how a high resolution HPLC-CAD platform can provide accurate and fast characterization of your LNP formulations.

In this episode of Teach Me in 10 we are joined by Adam Crowe, manager of analytical development at Precision NanoSystems Inc.